Icon Bioscience was founded in 2004, the headquarters are in Sunnyvale, California. This company focuses on using the verisome technology to approved or in market ophthalmic agents. They improve existing eye disease treatments. Icon’s leading product ‘Dexycu’ has completed phase III and an NDA is planned for 2017. It is used to reduce inflammation from cataract surgery. They target many diseases such as: ophthalmic indications, including glaucoma, macular edema, inflammation/infection associated with cataract surgery, and age-related macular degeneration.